BMS 354825 picks up where imatinib leaves off in CML

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1474, 2005-01, pp. : 5-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dasatinib: BMS 354825

By Adis International Limited

Drugs in R&D, Vol. 7, Iss. 2, 2006-01 ,pp. : 129-132

Adis International

Access to resources Recommend Favorite

BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia

By Doggrell Sheila A

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 1, 2005-01 ,pp. : 89-91

Informa Healthcare

Access to resources Recommend Favorite

Dasatinib off to a good start in imatinib-resistant CML

Inpharma, Vol. 1, Iss. 1523, 2006-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Value of imatinib uncertain in CML

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 479, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Imatinib mesylate promising for CML

Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite